A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD)

Utsha G Khatri, Kathleen Lee, Theodore Lin, Joseph L D'Orazio, Mitesh S Patel, Frances S Shofer, Jeanmarie Perrone, Utsha G Khatri, Kathleen Lee, Theodore Lin, Joseph L D'Orazio, Mitesh S Patel, Frances S Shofer, Jeanmarie Perrone

Abstract

Background: Despite the evidence in support of the use of buprenorphine in the treatment of OUD and increasing ability of emergency medicine (EM) clinicians to prescribe it, emergency department (ED)-initiated buprenorphine is uncommon. Many EM clinicians lack training on how to manage acute opioid withdrawal or initiate treatment with buprenorphine. We developed a brief buprenorphine training program and assessed the impact of the training on subsequent buprenorphine initiation and knowledge retention.

Methods: We conducted a pilot randomized control trial enrolling EM clinicians to receive either a 30-min didactic intervention about buprenorphine (standard arm) or the didactic plus weekly messaging and a monetary inducement to administer and report buprenorphine use (enhanced arm). All participants were incentivized to complete baseline, immediate post-didactic, and 90-day knowledge and attitude assessment surveys. Our objective was to achieve first time ED buprenorphine prescribing events in clinicians who had not previously prescribed buprenorphine in the ED and to improve EM-clinician knowledge and perceptions about ED-initiated buprenorphine. We also assessed whether the incentives and reminder messaging in the enhanced arm led to more clinicians administering buprenorphine than those in the standard arm following the training; we measured changes in knowledge of and attitudes toward ED-initiated buprenorphine.

Results: Of 104 EM clinicians enrolled, 51 were randomized to the standard arm and 53 to the enhanced arm. Clinical knowledge about buprenorphine improved for all clinicians immediately after the didactic intervention (difference 19.4%, 95% CI 14.4% to 24.5%). In the 90 days following the intervention, one-third (33%) of all participants reported administering buprenorphine for the first time. Clinicians administered buprenorphine more frequently in the enhanced arm compared to the standard arm (40% vs. 26.3%, p = 0.319), but the difference was not statistically significant. The post-session knowledge improvement was not sustained at 90 days in the enhanced (difference 9.6%, 95% CI - 0.37% to 19.5%) or in the standard arm (difference 3.7%, 95% CI - 5.8% to 13.2%). All the participants reported an increased ability to recognize patients with opioid withdrawal at 90 days (enhanced arm difference .55, 95% CI .01-1.09, standard arm difference .85 95% CI .34-1.37).

Conclusions: A brief educational intervention targeting EM clinicians can be utilized to achieve first-time prescribing and improve knowledge around buprenorphine and opioid withdrawal. The use of weekly messaging and gain-framed incentivization conferred no additional benefit to the educational intervention alone. In order to further expand evidence-based ED treatment of OUD, focused initiatives that improve clinician competence with buprenorphine should be explored.

Trial registration: ClinicalTrials.gov Identifier: NCT03821103.

Keywords: Behavioral incentives; Buprenorphine; Opioid use disorder.

Conflict of interest statement

None.

© 2022. American College of Medical Toxicology.

Figures

Fig. 1
Fig. 1
Consort diagram.
Fig. 2
Fig. 2
Changes in knowledge scores on buprenorphine.
Fig. 3
Fig. 3
Changes in attitudes toward ED-initiated buprenorphine.

References

    1. Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic. JAMA. 2020;324(16):1673–1674. 10.1001/jama.2020.17477
    1. US Centers for Disease Control and Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. . Accessed 10 January 2021.
    1. Soares WE 3rd, Melnick ER, Nath B, D'Onofrio G, Paek H, Skains RM, Walter LA, Casey MF, Napoli A, Hoppe JA, Jeffery MM. Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems. Ann Emerg Med. 2022;79(2):158–167.
    1. Weiner SG, Baker O, Bernson D, Schuur JD. One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. Ann Emerg Med. 2020;75(1):13–17. doi: 10.1016/j.annemergmed.2019.04.020.
    1. Kakko J, Alho H, Baldacchino A, Molina R, Nava FA, Shaya G. Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice. Front Psychiatry. 2019;10:592.
    1. Mahmoud S, Anderson E, Vosooghi A, Herring AA. Treatment of opioid and alcohol withdrawal in a cohort of emergency department patients. Am J Emerg Med. 2021;43:17–20. doi: 10.1016/j.ajem.2020.12.074.
    1. Monico LB, Oros M, Smith S, Mitchell SG, Gryczynski J, Schwartz R. One million screened: scaling up SBIRT and buprenorphine treatment in hospital emergency departments across Maryland. Am J Emerg Med. 2020;38(7):1466–1469. doi: 10.1016/j.ajem.2020.03.005.
    1. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207. 10.1002/14651858.CD002207.pub4.
    1. Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7. doi: 10.1016/j.jsat.2017.04.005.
    1. Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157. doi: 10.1186/s12875-019-1047-z.
    1. Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133. doi: 10.1370/afm.1595.
    1. Im DD, Chary A, Condella AL, et al. Emergency department clinicians' attitudes toward opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study. West J Emerg Med. 2020;21(2):261–271. doi: 10.5811/westjem.2019.11.44382.
    1. Foster SD, Lee K, Edwards C, et al. Providing incentive for emergency physician X-waiver training: an evaluation of program success and postintervention buprenorphine prescribing. Ann Emerg Med. 2020;76(2):206–214. doi: 10.1016/j.annemergmed.2020.02.020.
    1. D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–1644. doi: 10.1001/jama.2015.3474.
    1. Lowenstein M, Kilaru A, Perrone J, et al. Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. Am J Emerg Med. 2019;37(9):1787–1790. doi: 10.1016/j.ajem.2019.02.025.
    1. Hawk KF, D’Onofrio G, Chawarski MC, et al. Barriers and facilitators to clinician readiness to provide emergency department–initiated buprenorphine. JAMA Netw Open. 2020;3(5):e204561–e204561. doi: 10.1001/jamanetworkopen.2020.4561.
    1. Zuckerman M, Kelly T, Heard K, Zosel A, Marlin M, Hoppe J. Physician attitudes on buprenorphine induction in the emergency department: results from a multistate survey. Clin Toxicol. 2020;1–7.
    1. Rhee TG, D’Onofrio G, Fiellin DA. Trends in the use of buprenorphine in US emergency departments, 2002–2017. JAMA Netw Open. 2020;3(10):e2021209–e2021209. doi: 10.1001/jamanetworkopen.2020.21209.
    1. Title 21, Code of federal regulations, part 1306.07(b).
    1. Wiegand TJ. The new kid on the block—incorporating buprenorphine into a medical toxicology practice. J Med Toxicol. 2016;12(1):64–70. doi: 10.1007/s13181-015-0518-4.
    1. Levels of racism a theoretic framework and a gardener's tale. Am J Public Health. 2000;90(8):1212–1215. doi: 10.2105/AJPH.90.8.1212.
    1. Martin A, Kunzler N, Nakagawa J, et al. Get waivered: a resident-driven campaign to address the opioid overdose crisis. Ann Emerg Med. 2019;74(5):691–696. doi: 10.1016/j.annemergmed.2019.04.035.
    1. Saitz R, Friedmann PD, Sullivan LM, et al. Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives. J Gen Intern Med. 2002;17(5):373–376.
    1. Gong CL, Zangwill KM, Hay JW, Meeker D, Doctor JN. Behavioral economics interventions to improve outpatient antibiotic prescribing for acute respiratory infections: a cost-effectiveness analysis. J Gen Intern Med. 2019;34(6):846–854. doi: 10.1007/s11606-018-4467-x.
    1. Delgado MK, Shofer FS, Patel MS, et al. Association between electronic medical record implementation of default opioid prescription quantities and prescribing behavior in two emergency departments. J Gen Intern Med. 2018;33(4):409–411. doi: 10.1007/s11606-017-4286-5.
    1. LeSaint KT, Klapthor B, Wang RC, Geier C. Buprenorphine for opioid use disorder in the emergency department: a retrospective chart review. West J Emerg Med. 2020;21(5):1175–1181.
    1. Weimer MB, Tetrault JM, Fiellin DA. Patients with opioid use disorder deserve trained providers. Ann Intern Med. 2019;171(12):931–932. doi: 10.7326/M19-2303.
    1. Diamond D. Biden kills Trump plan on opioid-treatment prescriptions. The Washington Post. Jan. 27, 2021. . Accessed 1 February 2021.
    1. LeSaint KT, Ho RY, Heard SE, Smollin CG. California poison control system implementation of a novel hotline to treat patients with opioid use disorder. J Med Toxicol. 2021;17(2):190–196. doi: 10.1007/s13181-020-00816-1.
    1. Cook DA, Wittich CM, Daniels WL, West CP, Harris AM, Beebe TJ. Incentive and reminder strategies to improve response rate for internet-based physician surveys: a randomized experiment. J Med Internet Res. 2016;18(9):e244. doi: 10.2196/jmir.6318.
    1. Flanigan T, McFarlane E, Cook S. Conducting Survey Research among Physicians and Other Medical Professionals—A Review of Current Literature. In: Proceedings of the Survey Research Methods Section. American Statistical Association; 2008. p. 4136–47.
    1. Cunningham CT, Quan H, Hemmelgarn B, et al. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015;15(1):32. doi: 10.1186/s12874-015-0016-z.
    1. Brtnikova M, Crane LA, Allison MA, Hurley LP, Beaty BL, Kempe A. A method for achieving high response rates in national surveys of U.S. primary care physicians. PLOS ONE. 2018;13(8):e0202755. doi: 10.1371/journal.pone.0202755.
    1. Varshneya NB, Thakrar AP, Hobelmann JG, Dunn KE, Huhn AS. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl. J Addict Med. 2021. 10.1097/ADM.0000000000000922.
    1. Guo CZ, D'Onofrio G, Fiellin DA, et al. Emergency department-initiated buprenorphine protocols: a national evaluation. J Am Coll Emerg Physicians Open. 2021;2(6):e12606.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj